Objective: To develop a preoperative prognostic model in order to predict recurrence-free survival in patients with nonmetastatic kidney cancer. Methods: A multi-institutional data base of 1889 patients who underwent surgical resection between 1987 and 2007 for kidney cancer was retrospectively analyzed. Preoperative variables were defined as age, gender, presentation, size, presence of radiological lymph nodes and clinical stage. Univariate and multivariate analyses of the variables were performed using the Cox proportional hazards regression model. A model was developed with preoperative variables as predictors of recurrence after nephrectomy. Internal validation was performed by Harrell's concordance index. Results: The median follow-up was 23.6 months (1 -222 months). During the follow-up, 258 patients (13.7%) developed cancer recurrence. The median follow-up for patients who did not develop recurrence was 25 months. The median time from surgery to recurrence was 13 months. The 5-year freedom from recurrence probability was 78.6%. All variables except age were associated with freedom from recurrence in multivariate analyses (P , 0.05). Age was marginally significant in the univariate analysis. All variables were included in the predictive model. The calculated c-index was 0.747. Conclusions: This preoperative model utilizes easy to obtain clinical variables and predicts the likelihood of development of recurrent disease in patients with kidney tumors.
INTRODUCTION
Renal cell carcinoma is a heterogeneous disease with a highly variable prognosis. Although numerous prognostic factors have been described, no single factor has been shown as a perfect indicator of prognosis. Outcome prediction models also known as prognostic models combine several prognostic factors in order to better predict the prognosis. These models may be used by practitioners to guide treatment decisions, counsel patients, select follow-up schedules tailored to the risk of cancer progression, determine the need for adjuvant therapy and stratify patients for clinical trials. As far as renal cell carcinoma is considered, various prognostic models have been developed for both patients with localized and metastatic diseases (1 -11) . Models for localized disease can further be subcategorized as preoperative and postoperative models. The preoperative models might suffer from lack of accuracy because they do not have the advantage of incorporating powerful prognostic variables such as histological type and grade of tumor. An ideal preoperative model with very high accuracy is yet to be described and externally validated.
The objective of this study was to develop a preoperative prognostic model that can be used to predict recurrence-free survival after nephrectomy in patients with renal cancer and no sign of distant metastasis at the time of surgery. We used data from a multi-institutional database and defined a nomogram utilizing readily available clinical and radiological parameters to achieve a practical but also accurate preoperative prognostic model.
PATIENTS AND METHODS
Twenty-five institutions participated to the study. These centers contributed data retrospectively from all patients who underwent radical or partial nephrectomy between 1987 and 2007 for kidney tumors and had no evidence of distant metastasis at the time of surgery. Patients with von Hippel-Lindau disease and synchronous bilateral tumors were not included in the database. A datasheet was provided to all centers to enter the required data that were then pooled in one single database. The final database consisted of 1889 patients.
Preoperative variables were defined as age at the time of surgery, gender, clinical presentation, radiological size, presence of radiological lymph nodes and clinical stage. Clinical presentation was categorized as incidental, local symptoms or systemic symptoms. Incidental tumors were defined as those that were detected during evaluation of an unrelated medical condition, and the patients had no kidney tumorrelated symptoms at the time of diagnosis. Patients with Common Terminology Criteria for Adverse Effects (CTCAE) Grade 1 or greater symptoms (such as Grade 1 pain, urine color change or constitutional symptoms etc.) were regarded as symptomatic. Locally symptomatic patients were defined as those who presented with flank pain, flank or abdominal mass or hematuria. Patients with systemic symptoms were defined as those who presented with fever, weight loss, fatigue or signs and symptoms caused by paraneoplastic disorders. Those with both local and systemic symptoms were considered in the systemic symptoms group. Preoperative work-up for staging varied between the centers but mostly consisted of bone scans, blood biochemistry and computerized tomography (CT) scans of the chest, abdomen and pelvis. Some patients had magnetic resonance imaging (MRI) scans of the abdomen. Cross-sectional imaging (CT and/or MRI scans) were used to measure the radiological size, assign clinical stage and identify the presence of regional lymph nodes. The radiological size was defined as the largest diameter of the tumor. The presence of regional lymph nodes was defined as nodes .10 mm. Clinical T and N stages were assigned according to the 2002 TNM staging system of the American Joint Committee on Cancer (12) .
The follow-up protocols varied between centers. Generally, patients were followed up at 3 -12 monthly intervals by physical examination, routine laboratory evaluation, chest X-ray, CT or ultrasonography. The time to recurrence was defined as the interval from surgery to the first evidence of disease recurrence.
The end points of the study were time until the detection of kidney cancer recurrence and the time to last follow-up if the patient was alive, or time until death if the patient died without kidney cancer recurrence. Kidney cancer recurrence was defined as local or metastatic cancer recurrence or development of cancer in the opposite kidney. Outcomes were measured in terms of disease recurrence. Patients were either alive without metastases, dead without metastases or had disease recurrence (local or metastatic). Patients were censored at the time of death or last follow-up without metastasis. Progression-free probability was estimated using the Kaplan -Meier method. Univariate analysis of the variables was performed by the Cox proportional hazards regression model. Multivariate analysis was performed with the Cox proportional hazards regression model and 95% confidence intervals (95% CI) were calculated on 1000 bootstrap samples. The results of the analyses were used to model preoperative variables as predictors of recurrence after nephrectomy. Thus, a nomogram was constructed for the probability of recurrence-free survival. Internal validation of the model was performed by calculating Harrell's concordance index. All analyses were performed using S-plus 2000 professional software.
RESULTS
Characteristics of the 1889 patients are presented in Table 1 . The types of surgical procedures were as follows: 1655 patients open radical nephrectomy, 194 patients open partial nephrectomy, 36 patients laparoscopic radical nephrectomy and 4 patients laparoscopic partial nephrectomy. The smallest tumor was 9 mm and the largest tumor was 300 mm in size. Pathologic evaluations revealed clear cell carcinoma in 1431 patients (75.8%), papillary in 185 (9.8%) patients, chromophobe in 138 (7.3%) patients. In the remaining 135 (7.1%) patients, the histological subtype was reported as collecting duct carcinoma or unclassified/undetermined. The median follow-up was 23.6 months and ranged from 1 to 222 months. During the follow-up, 258 patients (13.7%) developed recurrent disease. The median follow-up for patients who did not develop recurrent disease was 25 months and ranged from 1 to 222 months. The median time from surgery to disease recurrence was 13 months and ranged from 1 to 153 months. The 5-year freedom from
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Preoperative nomogram for recurrence-free survival in renal cancer recurrence probability for the study cohort was 78.6% (95% CI 75.9 -81.3%). On univariate analysis, patient age, gender, mode of presentation, radiological size of the renal mass, clinical tumor stage and evidence of lymph nodes on imaging were significant predictors of recurrence. The results of univariate and multivariate analyses are presented in Table 2 . All of the variables except age were associated with freedom from recurrence in multivariate analyses (P , 0.05). However, since patient age was marginally significant in the univariate analysis, all variables including age were included in the predictive model. The nomogram constructed from the multivariate Cox regression coefficients is shown in Fig. 1 . Harrell's c-index developed across the 1889 patients was 0.747.
COMMENTS
Standard treatment for patients with renal cell carcinoma is radical or partial nephrectomy. Preoperative diagnosis is made with radiological evaluation in most of the cases and tissue diagnosis is seldom indicated. With no pathologic variables available, decision-making and patient counseling before nephrectomy are based mostly on clinical variables. An accurate tool for the prediction of prognosis would serve well for clinical decision-making and patient counseling. Preoperative predictive differentiation of patients is useful to choose patients for neoadjuvant treatment trials and possibly for neoadjuvant treatment protocols in the near future. The prediction of prognosis with preoperative clinical variables is also useful for patients whose pathologic variables are not available such as those treated with needle ablative procedures and morcellation of the specimen during laparoscopy.
Five preoperative prognostic models have been published to date (Table 3) 
generated a prognostic model to categorize patients in low-and high-risk groups in terms of disease recurrence according to the clinical size and mode of presentation (1). A similar model was also developed with data from three European institutes (2) . The main limitation of such models is that they omit individual differences in prognosis and instead categorize patients into limited number of risk groups. This results in clustering of patients with varying prognosis in the same group. Accordingly, these two models, although very easy to use, suffered low predictive accuracies in a multi-institutional external validation study (13) . The third published model is developed by a multi-institutional study from Canada and Europe. This model is a nomogram for the prediction of freedom from renal cell carcinoma-specific mortality (3). Nomograms are graphic charts that provide outcome probabilities tailored to the individual's characteristics and provide information for individual patient counseling. This study had a model development cohort and an external validation cohort, and the nomogram prediction at 5 years was 86.8% accurate. The fourth model is a preoperative nomogram that predicts the 12-year probability of metastatic renal cancer after radical or partial nephrectomy in patients with renal masses and no concurrent evidence of metastasis (4). It was based on data from Memorial Sloan-Kettering Cancer Center and Mayo Clinic. This model was internally validated with a bootstrapping technique and the resultant concordance index was 0.8. The fifth preoperative model was reported by authors from Japan. It is a preoperative nomogram based on the TNM classification and predicts cause-specific survival in patients with renal cell carcinoma (5 SD, standard deviation; numbers in parentheses are percentages.
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controversial to pool patients with and without metastatic disease in a single cohort. There are already predictive models widely in use for patients with metastasis (11) . There are several postoperative models that predict clinical outcomes based on clinical and pathologic data (6 -10) . It has been shown that models that incorporate pathological data perform better than preoperative models. The discriminating ability of four prognostic models was compared using an independent dataset containing more than 2404 patients from six European centers (13) . As previously mentioned, two of these were preoperative Yaycioglu and Cindolo models, and the other two were postoperative Kattan and UISS models (1,2,6,7) . The Kattan nomogram was consistently the most accurate model with a concordance index of 0.807 for recurrence-free survival followed by the UISS model. On the other hand, the same Kattan nomogram showed low predictive accuracy in a sample of 565 French patients with a concordance index of only 0.607 (14) . The significance of this variation in different datasets is not very clear because there is no threshold for concordance index to label a model as clinically useful or not (15) . Although factors such as differences in the definition of variables in different datasets may result in variations in the accuracy of a certain model (methodologic and spectrum transportability), it is also possible that a model that works well for a specific patient population may not necessarily be the best model for other patient populations (geographic transportability) (16) .
The prognostic variables that make our nomogram are age, sex, mode of presentation, tumor size, T stage and presence of lymph nodes. All of these variables have been shown as important prognostic indicators in previous studies (17 -26) . These variables are also easily available and reproducible, which makes the nomogram easy to be used in real-life clinical practice. However, some points should be mentioned. Categorizing patients in terms of their symptoms may at times be complex, especially when one has to differentiate between local and systemic symptoms on a retrospective analysis. Therefore, we categorized all patients with 
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Preoperative nomogram for recurrence-free survival in renal cancer any systemic complaints into systemic group, even if their primary complaint was local symptoms. However, interobserver variability is always a possibility. For tumor size, we chose to use the largest diameter on CT or MRI. It can be argued that calculation of tumor volume represents the tumor burden more accurately. However, since a largest tumor diameter is easier to calculate and leaves less space for inter-observer variability, we preferred to use it instead. Radiological determination of the exact number of involved lymph nodes may also be problematic. Therefore, we chose to categorize the patients as those with and those without lymph node involvement. There are debates going on over TNM classification and the definition and subcategorization of T stage, which is constantly evolving. It is probable that further refinements on the definition of T stage may be incorporated to the nomogram. However, this subject is to be investigated in the future external validation studies. The limitations of the study are its retrospective nature, relatively short follow-up and the lack of standardized follow-up protocol. On the other hand, the multi-center nature of the study and the number of the enrolled patients are positive aspects. The internal validation of the model resulted in a concordance index of 0.747. This c-index shows that the model has a good accuracy but it is not perfect. The model is yet to be externally validated. There is still room for improvement of the predictive ability of preoperative models. There are efforts to improve the predictive ability of the published postoperative models by integrating molecular markers to these models (27) . Improvements on the accuracy of needle biopsy of kidney tumors may allow incorporation of histologic characteristics and tissue molecular markers to the preoperative models as well (28) .
CONCLUSIONS
This model predicts the likelihood of the development of cancer recurrence in patients with kidney tumors before nephrectomy. It is a user-friendly nomogram and utilizes easyto-obtain clinical variables. The model is useful to counsel patients before surgery. It can be used as a tool to enroll patients in clinical trials and to choose which patients would be served best by possible neoadjuvant treatments in the future.
